Ethyl and Methyl Alcohol

Ethanol — Pharmacokinetics

Absorbed stomach+small intestine(↓by food, esp fatty). Metabolism: ADH→acetaldehyde→ALDH→acetate(→TCA cycle). Minor: MEOS(CYP2E1) — ↑at high chronic intake, INDUCIBLE → tolerance to own metabolism + ↑metabolism/toxicity of other CYP2E1 substrates(paracetamol — ↑hepatotoxicity risk in chronic drinkers).

ZERO-ORDER kinetics: ADH saturated at typical drinking levels → constant rate/time (NOT per concentration), ~10mL absolute alcohol/hr. Blood level falls LINEARLY not exponentially — “time to sober up” scales with amount drunk, not current level.

Ethanol — Mechanism (CNS)

↑GABA-A (like benzo/barbiturate — cross-tolerance, why benzos used in withdrawal) + ↓NMDA glutamate. Dual mechanism → dose-dependent depression: low dose=disinhibition/euphoria(“stimulant”-feeling, cortical control lost first) → incoordination/slurred speech/impaired judgement → sedation/resp depression/coma(high dose).

Ethanol — Chronic Effects & Withdrawal

Chronic: steatosis→alcoholic hepatitis→cirrhosis(SAME spectrum, dose/duration-dependent) · Wernicke-Korsakoff(thiamine deficiency — malnutrition+↓thiamine absorption) → give THIAMINE BEFORE glucose in malnourished/altered-consciousness patient(glucose metabolism consumes thiamine, can precipitate/worsen Wernicke’s) · peripheral neuropathy · cardiomyopathy · pancreatitis.

Withdrawal: chronic use → ↓GABA-A sensitivity + ↑NMDA number/sensitivity(compensatory) → abrupt stop unmasks EXCESS excitatory tone: tremor/anxiety(mild,early)→seizures→delirium tremens(severe, fatal risk — autonomic instability, hallucinations, confusion, ~48-72h post last drink). Benzodiazepines = mainstay (substitute for ethanol’s GABA action, controlled taper).

Ethanol — Interactions & Uses

Disulfiram: inhibits ALDH → acetaldehyde accumulates with alcohol → flushing/headache/N&V/hypotension(“disulfiram-ethanol reaction,” deliberate aversive deterrent). Similar disulfiram-like reaction(same ALDH-inhibition mechanism): metronidazole, some cephalosporins, chlorpropamide — CLASS of interaction, not one-off.

Uses: antiseptic/skin disinfectant(denatures microbial protein) · competitive ADH substrate antidote for methanol/ethylene glycol poisoning(higher ADH affinity than either toxic alcohol → outcompetes, prevents toxic metabolite formation).

Methanol — Toxicity Mechanism

Methanol itself ~non-toxic; danger = metabolites. ADH→formaldehyde→(ALDH)→FORMIC ACID = actual toxic agent → anion-gap metabolic acidosis(formate directly ↑gap) + characteristic OCULAR toxicity(formic acid selectively toxic to retinal ganglion cells/optic nerve via mitochondrial cytochrome oxidase inhibition → blurred vision, “snowfield” disturbance, potential permanent blindness — MOST distinctive feature vs other toxic alcohols).

Methanol — Management

Logic = BLOCK further formic acid formation: ethanol(classic, outcompetes at ADH) OR fomepizole(preferred where available — direct competitive ADH inhibitor, cleaner PK/side-effect profile) + NaHCO3(acidosis) + haemodialysis(removes unmetabolized methanol+formate, esp severe poisoning/inadequate renal clearance). Folinic/folic acid: cofactor for further formate→CO2+H2O metabolism → accelerates formate clearance, adjunct on top of blocking formation.

Ethylene Glycol (brief comparison)

Same ADH/ALDH logic → glycolic acid+oxalic acid(not formic acid) → severe metabolic acidosis + calcium oxalate crystals in renal tubules(AKI; oxalate crystals on urine microscopy = distinguishing finding vs methanol’s ocular toxicity). Management IDENTICAL logic: ethanol/fomepizole(block ADH) + bicarbonate + haemodialysis(severe cases).

Clinical Relevance

Methanol/ethylene glycol management = clean illustration of “block the metabolism, not just treat symptom” — parent compounds relatively harmless, treatment aims entirely at preventing conversion to toxic metabolites via competitive-substrate strategy(higher enzyme affinity), not receptor blockade. SAME underlying principle(shared, saturable, competable metabolic machinery) explains ethanol’s own CYP2E1-mediated drug interactions in chronic drinkers — one idea, three superficially separate facts.

Ethanol

Pharmacokinetics

Ethanol is absorbed rapidly from the stomach and small intestine (absorption slowed by food, particularly fatty food, which delays gastric emptying) and metabolized predominantly in the liver by a two-step oxidation: alcohol dehydrogenase (ADH) converts ethanol to acetaldehyde, and aldehyde dehydrogenase (ALDH) converts acetaldehyde to acetate (subsequently entering the citric acid cycle). A minor pathway, the microsomal ethanol-oxidizing system (MEOS, via CYP2E1), contributes more at higher chronic intake and is inducible — the mechanistic basis for tolerance to ethanol’s own metabolism with chronic use, and for the increased metabolism (and toxicity) of other CYP2E1 substrates (including paracetamol, relevant to alcoholic patients’ increased paracetamol hepatotoxicity risk) in chronic drinkers.

Zero-order kinetics: at typical drinking concentrations, ADH is already saturated, so ethanol is eliminated at a constant rate per unit time (not per unit concentration) — roughly 10 mL of absolute alcohol per hour in an average adult — unlike the first-order kinetics that govern most drugs. This is why blood alcohol concentration falls linearly over time rather than exponentially, and why “time to sober up” scales roughly linearly with how much was drunk, not proportionally to current blood level.

Mechanism of Action (CNS Effects)

Ethanol potentiates inhibitory GABA-A receptor activity (similar to benzodiazepines/barbiturates, contributing to cross-tolerance and the rationale for using benzodiazepines in alcohol withdrawal) and inhibits excitatory NMDA glutamate receptor activity — a dual mechanism (enhance inhibition, block excitation) that together produces the broad, dose-dependent CNS depression: disinhibition and mild euphoria at low doses (paradoxically “stimulant”-feeling because inhibitory cortical control is lost first), progressing through incoordination, slurred speech, and impaired judgement to sedation, respiratory depression, and coma at high doses — the same fundamental progression, and the same underlying reason, as the CNS-depressant classes it cross-tolerates with.

Chronic Effects and Withdrawal

Chronic alcohol use: hepatic steatosis → alcoholic hepatitis → cirrhosis (a genuine dose/duration-dependent spectrum, not three unrelated diseases), Wernicke-Korsakoff syndrome (thiamine deficiency, from poor nutrition and alcohol’s interference with thiamine absorption — a specific, preventable/treatable neurological complication, hence the practice of giving thiamine before glucose in a malnourished/alcoholic patient with altered consciousness, since glucose metabolism consumes thiamine and can precipitate or worsen Wernicke’s encephalopathy if thiamine stores are already marginal), peripheral neuropathy, cardiomyopathy, and pancreatitis.

Withdrawal syndrome: reflects the flip side of chronic GABA-potentiation/NMDA-inhibition — chronic exposure downregulates GABA-A receptor sensitivity and upregulates NMDA receptor number/sensitivity (compensatory adaptations to the drug’s presence), so abrupt cessation unmasks a relative excess of excitatory tone: tremor and anxiety (mild, early) progressing to seizures and delirium tremens (severe, potentially fatal — autonomic instability, hallucinations, confusion, typically 48–72 hours after the last drink). Benzodiazepines are the mainstay of withdrawal management precisely because they substitute for ethanol’s GABA-potentiating action, allowing a controlled, tapered withdrawal rather than an abrupt one.

Drug Interactions and Uses

Disulfiram: inhibits aldehyde dehydrogenase, causing acetaldehyde to accumulate if alcohol is consumed — produces flushing, throbbing headache, nausea, vomiting, and hypotension (the “disulfiram-ethanol reaction,” an unpleasant, deliberately aversive deterrent used in alcohol dependence treatment). Several other drugs (metronidazole, some cephalosporins, chlorpropamide) produce a similar disulfiram-like reaction with alcohol via the same ALDH-inhibition mechanism, worth knowing as a class of interaction rather than a one-off fact about disulfiram alone.

Uses of ethanol itself, pharmacologically: historically as an antiseptic/skin disinfectant (denatures microbial protein), and — the more frequently examined use — as a competitive substrate antidote for methanol and ethylene glycol poisoning (see below), since ethanol has a much higher affinity for alcohol dehydrogenase than either toxic alcohol, effectively outcompeting them for the enzyme and preventing formation of their toxic metabolites.

Methanol

Toxicity Mechanism

Methanol itself is relatively non-toxic; its danger comes entirely from its metabolites. Alcohol dehydrogenase oxidizes methanol to formaldehyde, which is rapidly further oxidized (by aldehyde dehydrogenase) to formic acid — formic acid is the actual toxic agent, responsible for both the severe anion-gap metabolic acidosis (accumulating formate directly contributes to the anion gap) and the characteristic ocular toxicity (formic acid is selectively toxic to retinal ganglion cells and the optic nerve, via inhibition of mitochondrial cytochrome oxidase in these especially metabolically active cells — producing blurred vision, “snowfield” visual disturbance, and potentially permanent blindness, the single most distinctive clinical feature separating methanol poisoning from other toxic alcohol ingestions).

Management

The management logic follows directly from the mechanism: block further formic acid formation by outcompeting methanol for alcohol dehydrogenase, either with ethanol (classic antidote, given orally or IV to maintain a specific target blood level, competing at ADH by virtue of much higher affinity) or, preferably where available, fomepizole (a direct competitive ADH inhibitor, with a cleaner pharmacokinetic and side-effect profile than using ethanol itself as a “drug”) — plus correcting the metabolic acidosis (sodium bicarbonate) and haemodialysis to remove both unmetabolized methanol and accumulated formate directly, particularly in severe poisoning or when renal function to clear formate is inadequate. Folinic acid/folic acid is a specific adjunct — folate is a cofactor for the enzyme that further metabolizes formate to CO2 and water, so supplementing it accelerates formate clearance by the body’s own detoxification pathway, on top of blocking further formation.

Ethylene Glycol — Brief Comparison

Ethylene glycol (antifreeze) shares methanol’s core toxicity logic — metabolized by the same ADH/ALDH pathway to toxic products (glycolic acid and oxalic acid, rather than formic acid) — causing severe metabolic acidosis and, distinctively, calcium oxalate crystal deposition in the renal tubules (acute kidney injury, and a specific urine-microscopy finding — oxalate crystals — that helps distinguish it from methanol poisoning) rather than methanol’s characteristic ocular toxicity. Management follows the identical logic: ethanol or fomepizole to block ADH, bicarbonate for acidosis, haemodialysis for severe cases.

Clinical Relevance

The methanol/ethylene glycol management strategy is one of the cleanest illustrations in pharmacology of “block the metabolism, not just treat the symptom” — the parent compounds are relatively harmless, so treatment aims entirely at preventing their conversion to the actually toxic metabolites, using ethanol/fomepizole’s higher enzyme affinity as a competitive-substrate strategy rather than a receptor-blocking one. This is mechanistically the same principle (competing for a shared enzyme) that explains why ethanol itself, in the chronic drinker, alters the metabolism of other drugs sharing its CYP2E1 pathway — one underlying idea (shared, saturable, competable metabolic machinery) explaining three superficially separate facts.

Ethanol’s zero-order elimination (linear blood level vs time) contrasted with a first-order-eliminated drug’s exponential curve.
Methanol/ethylene glycol ADH-ALDH metabolic pathway to their toxic metabolites, with ethanol/fomepizole marked as competitive blockers at the ADH step.
Alcohol withdrawal timeline (tremor → seizures → delirium tremens) against the GABA-downregulation/NMDA-upregulation mechanism.